Sandoz

Showing 15 posts of 75 posts found.

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

March 22, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Biogen, Eisai, FDA, Merck, NICE, Pfizer, Roche, Sandoz

This week was a bad week for clinical trials. While the FDA put Roche and AbbVie’s multiple myeloma trial on …

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

March 15, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Acadia Pharmaceuticals, FDA, Sandoz, brexit, genomics, pharma, pharmacovigilance, top 10

The US Department of Justice has launched an investigation into the sales and marketing practices of San Diego firm Acadia …

richard-francis-big-image

Sandoz CEO Richard Francis to step down

March 14, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Novartis, Sandoz, appointment, pharma

Richard Francis is set to step down his role as Chief Executive of Novartis’ generics arm Sandoz after five years’ …

facilities_lg06

Indivior launches authorised generic version of opioid addiction treatment Suboxone as rival generic drugmakers enter market

February 21, 2019
Sales and Marketing Alvogen, Dr Reddy's, Novartis, Sandoz, indivior

Indivior has announced the launch of an authorised generic version of Suboxone Film (buprenorphine/naloxone) a combination medicine used to treat …

Novartis inks deal with Canadian cannabis firm Tilray

December 18, 2018
Research and Development Marijuana, Novartis, Sandoz, Tilray, cannabis

Shares in Canadian cannabis company Tilray jumped by more than 11% today after the British Columbia-based firm announced its entry …

nhs_sign

NHS to save £300 million by switching to Humira biosimilars

November 27, 2018
Manufacturing and Production, Sales and Marketing AbbVie, Humira, Mylan, NHS, Sandoz, adalimumab, biosimilars, pharrma

NHS England has announced that the health service is set to save £300 million by switching to biosimilar versions of …

novartis_outside_1

Novartis denies potential split with Sandoz

November 15, 2018
Business Services, Manufacturing and Production Business, M&A, MA, Novartis, Sandoz, acquisition, mergers

Swiss newspaper Tages-Anzeiger has reported that Novartis is preparing for a split with long-term partner Sandoz. The two companies merged …

Novartis sells key Sandoz US portfolios to Aurobindo for $1bn

September 6, 2018
Sales and Marketing Aurobindo, Novartis, Sandoz, pharma

Novartis has revealed it is to sell the dermatology and generic US oral solids portfolios of its generics arm Sandoz …

Medicines in an automated pharmacy

EU Commission grants market authorisation for Sandoz’ Humira biosimilar

July 30, 2018
Sales and Marketing FDA, Sandoz, approval, biosimilar, european commision

The European Commission has granted marketing authorisation to Sandoz’ biosimilar Hyrimoz for use in all indications, including rheumatoid arthritis, plaque …

tim_de_gavre

Head of Sandoz UK becomes BGMA chair

May 31, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sandoz, appointment, bgma, pharma

Tim de Gavre has been announced as the new chair for the British Generic Manufacturers Association (BGMA), a position he …

novartis_outside_1

Novartis’ Sandoz scores EU approval for Remicade biosimilar

May 24, 2018
Sales and Marketing EU, Europe, Novartis, Remicade, Sandoz, Zessly, pharma

The European Commission has given its approval to Sandoz, Novartis’ generics and biosimilars unit, for its biosimilar version of Janssen’s …

top_ten

Top Ten most popular articles on Pharmafile.com this week

May 4, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, EMA, Kymriah, Novartis, Porton Biopharma, Regeneron, Roche, Sandoz, Sanofi, Shire, Takeda, biosimilars, dementia

It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due …

Sandoz US woes continue with biosimilar rejection

May 3, 2018
Sales and Marketing Novartis, Sandoz, biosimilars, biotech, drugs, pharma, pharmaceutical

In Novartis’ recently released Q1 results, which largely beat analysts’ estimates, Sandoz was a black spot on its record – …

novartis_side_building

Novartis expands Pear partnership to tackle opioid and substance use disorder

April 23, 2018
Research and Development, Sales and Marketing Novartis, Pear Therapeutics, Sandoz, opioids, pharma, substance use disorder

Novartis has announced that it will expand its current partnership with Pear Therapeutics, signed in March, as it reveals that …

sandoz_3

Novartis steps into the medical marijuana business

March 20, 2018
Manufacturing and Production, Sales and Marketing Medical marijuana, Novartis, Sandoz, biotech, drugs, pharma, pharmaceutical

Canada’s burgeoning medical marijuana industry has finally drawn in a big pharma player. Tilray, a producer of medical cannabis products, …

The Gateway to Local Adoption Series

Latest content